# First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

> **NCT06531447** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The National Center of Oncology, Azerbaijan** · enrollment: 200 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06531447
- **Lead sponsor:** The National Center of Oncology, Azerbaijan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-05
- **Primary completion:** 2017-11
- **Final completion:** 2027-05
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06531447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06531447, "First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06531447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*